Bluebird shares tank after FDA puts another hold on its long delayed sickle cell gene therapy
Bluebird bio has been hit with another hold on one of its gene therapy programs.
The company announced Monday that the FDA had placed a partial hold on its sickle cell gene therapy trials for children under the age 18, after one adolescent patient was diagnosed with persistent anemia.
The biotech’s scientists are still trying to determine the cause of the patient’s anemia, but the company emphasized the individual is in otherwise good health and has not suffered any of the pain crises that are a hallmark of the disease. The anemia, they noted, is not severe enough to require transfusions.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
